logo-loader
Imugene Ltd

Imugene raises $3M from option plan to advance immunotherapy studies

Imugene is developing an immunotherapy to treat gastric cancer.

1-shutterstock_233501644.jpg
Immuno-oncology is a highly promising field

Imugene (ASX:IMU) has raised circa $3 million as part of an option plan which expired on 31 March 2017, at a price of $0.015 per share.

The new capital places Imugene in a solid position to continue the development of its clinical candidate, HER-Vaxx.

HER-Vaxx is a cancer immunotherapy designed to treat HER-2 positive gastric cancer, a cancer with increased levels of a growth-promoting protein called the HER-2 receptor.

Immuno-oncology is a relatively new but highly promising field that uses the method of activating a patient's immune system against tumour growth.

Imugene’s three prominent existing shareholders, Private Portfolio Managers, Platinum Asset Management and Celtic Capital, have increased their investment in Imugene via their roles as underwriters to the plan.

In January 2016, Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets.

This partnership has the potential to create B Cell peptide vaccines that would replace or augment conventional monoclonal antibodies.

Importantly, Imugene filed four new patent applications with IP Australia in December 2016 related to mimotope B-cell vaccine compositions.

The company’s share price increased circa 78% during the past six months, last trading at $0.016.

Quick facts: Imugene Ltd

Price: $0.02

Market: ASX
Market Cap: $75.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the...

on 8/7/19

2 min read